BiotechTube

STRO-004 + Pembrolizumab

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head and Neck Squamous Cell Carcinoma HNSCC

Conditions

Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer

Trial Timeline

Nov 7, 2025 → Apr 1, 2028

NCT ID
NCT07227168

About STRO-004 + Pembrolizumab

STRO-004 + Pembrolizumab is a phase 1 stage product being developed by Sutro Biopharma for Head and Neck Squamous Cell Carcinoma HNSCC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07227168. Target conditions include Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer.

What happened to similar drugs?

11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma HNSCC were approved

Approved (11) Terminated (0) Active (9)
✅Galcanezumab-GnlmEli LillyApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved
✅Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅Erenumab 70 mg + Erenumab 140 mg + PlaceboAmgenApproved
✅Rimegepant + ZavegepantPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07227168Phase 1Recruiting

Competing Products

20 competing products in Head and Neck Squamous Cell Carcinoma HNSCC

See all competitors
ProductCompanyStageHype Score
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
Abametapir Lotion 0.74% w/wDr. Reddy's LaboratoriesPhase 1
26
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + PlaceboDr. Reddy's LaboratoriesPhase 1
26
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40